Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 5;225(1):30-33.
doi: 10.1093/infdis/jiab556.

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Yaki Saciuk  1 , Jennifer Kertes  1 , Naama Shamir Stein  1 , Anat Ekka Zohar  1
Affiliations

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

Yaki Saciuk et al. J Infect Dis. .

Abstract

A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January-February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August-October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%-93.2%) and adjusted VE was 89.1% (95% CI, 87.5%-90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.

Keywords: COVID-19; Pfizer-BioNTech vaccine; SARS-CoV-2; mRNA BNT162b2; vaccine effectiveness.

PubMed Disclaimer

Comment in

References

    1. Hopkins Tanne J. Covid-19: FDA panel votes to authorize Pfizer BioNTech vaccine. BMJ 2020; 371:m4799. - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15. - PMC - PubMed
    1. Leshem E, Wilder-Smith A. COVID-19 vaccine impact in Israel and a way out of the pandemic. Lancet 2021; 397:1783–5. - PMC - PubMed
    1. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397:1819–29. - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, et al. . BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2020; 384:1412–23. - PMC - PubMed